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Objetivo: poco se conoce sobre el impacto de orlistat en el sistema leptina. Estudiamos la respuesta de la leptina plasmática y la sensación de 
saciedad tras dos días de tratamiento con orlistat sin dieta hipocalórica ni pérdida de peso.
Material y métodos: reclutamos veinte mujeres obesas en nuestras consultas externas de medicina. Habían recibido restricción dietética y 
modificación del estilo de vida, pero se habían mantenido obesas con peso corporal estable durante seis meses antes de su inclusión en el estudio.
Resultados: las pacientes tomaron 120 mg de orlistat 3 veces al día y mantuvieron su dieta habitual. Al inicio y dos días después del tratamiento 
con orlistat se repitieron el examen físico, la sensación de hambre y la analítica. No hubo diferencias significativas en el consumo de energía 
de la dieta, el peso corporal y la relación cintura-cadera, así como en glucosa sérica, insulina y péptido C. Solamente las concentraciones de 
leptina y triglicéridos en suero disminuyeron (p: 0,0001 y 0,01, respectivamente). La disminución de la concentración de leptina en suero se 
correlacionó positivamente con cambios en la concentración de triglicéridos (p: 0.01, r2: 0,45). La sensación de hambre aumento antes de la 
cena y se correlacionó negativamente con la disminución de la leptina (p: 0,0001, r2: 0,74) y triglicéridos (p: 0,02, r2: 0.59).
Conclusión: estos datos sugieren que la malabsorción parcial de grasas por el tratamiento con orlistat disminuye rápidamente los niveles plas-
máticos de triglicéridos y leptina. Este descenso se asoció con aumento del apetito antes de la ingesta que sigue a la comida principal del día.
Abstract
Objective: Little is known about the impact of orlistat on the leptin system. We studied the plasma leptin and satiety sensation response for two 
days of orlistat treatment without hypocaloric diet and weight loss.
Material and methods: Twenty obese female subjects were recruited from our medical outpatient clinics. All of these subjects had previously 
received advice on dietary restriction and lifestyle modification, but remained obese with a stable body weight for at least six months before 
recruitment for the study. 
Results: Subjects were given 120 mg orlistat 3 times daily and were asked to maintain their usual diet. At baseline and two days after the 
treatment with orlistat, physical examination, hunger and blood analysis were repeated. There were no significant differences observed regarding 
energy dietary intake, body weight and waist-hip ratio, or in plasma glucose, insulin c-peptide concentrations. Only plasma leptin and triglycerides 
concentrations decreased (p: 0.0001 and 0.01 respectively). Decrease in plasma leptin concentration was positively correlated with changes 
observed in plasma triglycerides concentration (p: 0.01, r2: 0.45). Pre-dinner hunger increased and was negatively correlated with decrease in 
leptin (p: 0.0001, r2: 0.74) and triglycerides (p: 0.02, r2: 0.59).
Conclusion: These data suggest that the partial fat malabsorption induced by the treatment with orlistat quickly reduces plasma triglycerides 
and leptin. This decrease is associated with increased appetite before intake following the main meal of the day.
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INTRODUCTION
Obesity is a chronic and costly disease which is increasing prev-
alence in many countries around the world. Hypo-caloric diet is the 
cornerstone of its treatment, but compliance is sometimes very 
difficult and almost impossible in the long term. Pharmaceutical 
strategies in the treatment of obesity include: drugs that regulate 
food intake, thermo genesis, fat absorption or fat metabolism (1).
Orlistat is a hydrogenated derivative of a fungal lipase inhibitor 
that blocks lipases and decreases triglyceride digestion in the 
intestinal lumen. Previous studies have confirmed the efficacy of 
orlistat in weight reduction with an improvement in cardiovascular 
risk factors among obese subjects (2). 
Little is known about the impact of orlistat on the leptin sys-
tem. Leptin is an adipocyte-derived hormone with important 
hypothalamic effects on the regulation of food intake and energy 
expenditure. In the fed state, circulating concentrations of leptin 
reflect the amount of energy stored in fat and correlate positively 
with adiposity indices. Individuals with similar degrees of adiposity 
exhibit great variations in plasma leptin concentrations. Hormonal 
and nutritional factors have been proposed to influence this (3). 
Caloric deprivation and loss of fat cell mass have been shown 
to decrease plasma leptin concentration. This observation has led to 
the hypothesis that leptin serves as a signal from the adipose tissue 
to the brain, where it acts as a regulator of satiety. However, during 
24 hours of fasting Haluzik et al. (4) described a 0.5% loss of their total 
body fat, while plasma leptin concentrations fell by 50%. It appears 
unlikely that the small change observed in fat mass could have been 
responsible for the profound decrease in plasma leptin concentrations.
Orlistat may cause an increase in appetite because of decreased 
absorption of dietary triglycerides. There are contradictory find-
ings between the studies that examined the effects of orlistat on 
satiety (5-7).
In view of the postulated role of leptin as a satiety factor, we felt 
it would be of interest to determine plasma leptin response to two 
days of orlistat treatment without hypo-caloric diet. The choice of 
this short period aims at ruling out the loss of fat mass from the 
observed results.
METHODS AND PROCEDURES
Twenty obese female subjects were recruited from the medi-
cal outpatient clinic. These subjects were initially referred to the 
hospital for weight management. All of them had received pre-
vious advice on dietary restriction and lifestyle modification, but 
remained obese with a stable body weight for at least six months 
before recruitment for the study. 
Exclusion criteria included: secondary obesity, pregnancy, 
lactation, childbearing potential with inadequate contraceptive 
measures, psychiatric or neurological disorders, alcohol or other 
substance abuse, previous gastrointestinal tract surgery for weight 
reduction, significant gastrointestinal symptoms, a history or the 
presence of malignancy, a significant history of cardiovascular 
complications or renal impairment.
We conducted an open-label, prospective cohort study. After 
giving written informed consent, eligible subjects underwent an 
assessment process including medical history, dietary intake 
using two days of food records, physical examination and meas-
urement of laboratory variables. 
All subjects were given orlistat 120 mg capsules before break-
fast, lunch and dinner. Subjects were asked to maintain their usual 
diet. All of them returned to the clinic two days later, where phys-
ical examination, measurement of laboratory variables, dietary 
intake records and subjective appetite sensations were repeated 
and compliance with orlistat treatment was ensured. Analytical 
determinations were performed after 8 hours fasting. 
Dietary intake was measured using a two day food diary. Entries 
were verified together with the patient by a dietitian using food 
models. Nutritional composition was determined by a Spanish 
DIAL program (8). 
Subjects were asked about their feelings of hunger and their 
desire to eat before lunch and dinner. For the assessment of 
subjective appetite sensations, a visual analogue scale was used. 
Patients were asked to make a vertical mark across the line cor-
responding to their feeling at the present time. Quantification of 
the measurement was made by measuring the distance from the 
left end of the line to the mark on a 100 mm line from “not at all” 
(0 mm) to “extremely” (100 mm). 
Laboratory variables included fasting plasma levels of glucose, 
triglycerides, total cholesterol and high density lipoprotein choles-
terol (HDL-C), which were measured on a Hitachi 911 automated 
analyzer (Boehringer Mannheim, Germany) using reagent kits sup-
plied by the analyzer manufacturer. The precision performance 
of these assays was within the manufacturer’s specifications. 
Levels of low-density lipoprotein cholesterol (LDL-C) were calcu-
lated using the Friedewald equation. Plasma total leptin, insulin 
and C-peptide were evaluated using a commercially available RIA 
method.
Data were analyzed using the Statistical Package for the 
Social Sciences for Windows, version 22.0 (SPSS Inc., Chicago, 
IL, USA). Descriptive statistics of the sample are presented. All 
results are shown as mean + SE. We used the Wilcoxon test for 
within-patient comparisons between baseline and post-treat-
ment measurements. Spearman correlation coefficients were 
determined to examine the relationships between percentages 
of changes. The value p < 0.05 was considered to be statisti-
cally significant.
RESULTS
All the patients were included and there were no losses record-
ed during the following, therefore, 20 people completed the pro-
tocol study.
Table I shows dietary energy intake, anthropometrics and 
laboratory results at baseline, and after two days with orlistat 
treatment. There were no significant differences regarding dietary 
energy intake, body weight and waist-hip ratio, or plasma glucose, 
insulin and C-peptide concentrations. 
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Plasma leptin and triglycerides concentrations decreased sig-
nificantly after two days of treatment without dietary restrictions.
After orlistat treatment, hunger and desire to eat before lunch 
and dinner increased, but only pre-dinner hunger showed statis-
tical significance (p = 0.01).
Figure 1 shows changes in plasma leptin concentration 
after two days with orlistat treatment, positively correlated with 
changes in plasma triglycerides concentration (p = 0.001, R2: 
0.449, beta 0.67).
Differences between pre/post treatment on hunger sensation 
before dinner correlated with changes in plasma leptin (R2 = 
0.75, p < 0.001, beta: -0.62) (Fig. 2A) and with changes in plas-
ma triglycerides concentration (R2 = 0.60, p = 0.02, beta: -0.35) 
(Fig. 2B).
DISCUSSION
In this study, all patients had made previous attempts to lose 
weight by dietary restriction and other lifestyle modifications, 
but weight reducing effects were only short lived. To examine 
the effect of orlistat on fuel metabolism and related hormones 
without the confounding factor of a hypocaloric diet and weight 
loss, subjects were asked to maintain their habits/ food behavior.
Orlistat is minimally absorbed, thus, no systemic direct effects 
in the regulation of food intake are expected. It is a potent, spe-
cific and reversible inhibitor of gastric and pancreatic lipases that 
reduces fat absorption by approximately 30% (2).
We have observed that plasma leptin reduction derived from 
orlistat treatment was associated with a concomitant reduction 
in triglycerides in these obese subjects (Fig. 1). It is not certain 
whether orlistat has a direct effect on leptin levels independ-
ent of weight reduction. Nevertheless, the absence of a decline 
in body weight within the two days of treatment, and the good 







Energy dietary intake (kcal/d) 1,896 ± 793 1,852 ± 683 N.S.
Total daily fat intake (g) 75.4 ± 14.3 73.8 ± 18.6 N.S.
Weight (kg) 97 ± 9.2 98.2 ± 8.5 N.S.
Body mass index (kg/m2) 35 ± 4 35 ± 6 N.S
Waist circumference (cm) 105.3 ± 10.3 105.1 ± 11 N.S.
Hip circumference (cm) 116.5 ± 8.6 116.2 ± 8.9 N.S.
Triglycerides (mg/dl) 175 ± 42 163 ± 37 0.01
Glucose (mg/dl) 94 ± 8 86 ± 12 N.S.
Total cholesterol (mg/dl) 236 ± 25 229 ± 32 N.S.
HDL cholesterol (mg/dl)
Leptin 28.4 ± 10 21.3 ± 6 0.0001
Insulin 14.4+1.4 14.15+0.3 N.S.
C-peptide 2.8 ± 0.7 2.2 ± 0.2 N.S.
Hunger pre-lunch 73 ± 12 79 ± 18 N.S.
Hunger pre-dinner 66 ± 11 78 ± 14 0.01
N.S.: not significant differences. Data are shown as means ± SEM. Statistics analysis has been made with a paired Wilcoxon t-test.
Figure 1. 
Linear regression analysis between the difference of leptin and difference of plas-
matic triglycerides after two days orlistat treatment. Dashed lines indicate the 
respective upper and lower 95% confidence intervals. R2: Correlation coefficient 
squared. Dif Lep: Difference leptin levels from basal to two days orlistat treatment. 
Dif TGL: Difference leptin levels from basal to two days orlistat treatment.
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 correlation of leptin and triglyceride decreases, support the notion 
that orlistat induced triglyceride decrease could be the key to 
leptin response. 
There is a large mass of evidence demonstrating that insulin 
responses to meals are the primary mediator of changes in leptin 
production observed during energy restriction (9). But Western 
dietary patterns and high-fat diet have been positively associated 
with plasma leptin concentrations in women and men (10).
Orlistat improves postprandial lipemia by reducing dietary 
triglyceride absorption (11,12). The combination of gemfibrozil 
and orlistat is extremely effective in reducing plasma triglyceride 
le vels (13) and orlistat therapy without concomitant hypocaloric 
diet improved triglyceride levels (14). Reduction of plasma triglyc-
eride levels could reduce leptin resistance in obese subjects and 
hence, decrease plasma leptin levels. Plasma triglycerides may 
underlie the impairment in blood-brain barrier transport of leptin 
in obesity. Rodrigues et al. (15) showed a decrease in cerebro-
spinal fluid/plasma leptin ratio after orlistat therapy, but not with 
fenproporex neither with sibutramine. 
In mice, diet-induced obesity increased triglycerides and 
reduced leptin uptake by the brain. Sixteen hours of fast-
ing reduced triglycerides and increased leptin uptake. Further-
more, reduction of triglyceride levels by pharmacological treat-
ment with gemfibrozil enhanced leptin transport (16). These 
results could explain why mice, which are unable to synthesize 
triglycerides, are more sensitive to leptin infusions (17). Thus, 
lowering triglycerides may be therapeutically useful in enhancing 
the effects of leptin on weight loss.
The primary importance of leptin in the regulation of ener-
gy homeostasis is for reduced leptin production to function as 
a signal of negative energy balance and low energy reserves. 
Obesity appears to be generally associated with high circulating 
leptin levels and reduced responsivity to leptin. The major effect 
of leptin administration in leptin deficiency on food intake with 
normalization of hyperphagia (18) but in obesity, high circulating 
leptin levels are unable to suppress feeding because of leptin 
resistance. Decreased plasmatic leptin levels in obese patients to 
normal levels could be an objective of treatment to avoid this leptin 
resistance and improve the anorexic leptin action (19). 
Plasma leptin levels depend not only on the size of adipose tis-
sue mass, because fasting decreases leptin levels without marked 
changes in the body fat mass. The degree of short-term caloric 
restriction has an effect on acute changes in plasma leptin con-
centration that may not be correlated with fat mass loss. Boden et 
al. (20) observed a 72% decrease in plasma leptin levels in normal 
volunteers after 52 hours fasting, suggesting that it is regulated 
by factors other than changes in body fat mass. Subsequently, 
other authors showed similar results. Klein et al. (21) observed 
that at 22 hours fasting, leptin production rates decreased in 
adipose tissue, and Haluzik et al. (22) observed that 24-h fasting 
significantly decreased plasma leptin.
The impact of orlistat on plasma leptin levels in obese patients 
has not been extensively studied. Brook et al. (23) showed a leptin 
decrease in a 3 month trial. Derosa et al. (24) observed a faster 
decrease in leptin compared with the control group in 254 type 
2 diabetic patients, after 12 months of orlistat treatment. Hsieh 
et al. (25), after one year of treatment in Asian obese patients, 
observed that over the same range of BMI, body fat% and waist 
circumference loss, the orlistat treatment group experienced 
more significant changes in plasma levels of leptin than the con-
trol group. On the other hand, Ozcelik et al. (26) showed, after 
12 weeks, a similar decrease in plasma leptin in 14 patients who 
received orlistat and 10 patients that received placebo. 
In all these studies, there was a weight loss that distorted 
results. We only found one publication studying the response of 
leptin to orlistat, without the effect of weight loss from our study. 
Sahin et al. (27) found in 34 obese patients that a single dose 
of 120 mg orlistat produced no changes in postprandial plasma 
leptin levels, although it increased a little in patients who had 
Figura 2. 
A-B. Linear regression analysis between the difference of hunger sensation prior 
to dinner and difference of leptin (A), difference of plasmatic triglycerides (B). 
Dashed lines indicate the respective upper and lower 95% confidence intervals. 











R2 Lineal = 0,599





10 15 20 25 30 35









y = -1,4 + -0,25*x
y = -5,73 + -1,06*x
296 A. Rodríguez-Valle et al.
[Nutr Hosp 2016;33(2):292-297]
taken prlistat. Their results do not correspond with ours, maybe 
because their patients had a single dose of orlistat. Fat intake 
may be inadequate because no differences were observed in 
postprandial triglycerides. 
More studies are needed as regards the response of postpran-
dial leptin. In our study, two days of orlistat treatment induced 
plasma triglyceride and leptin reductions, which were correlated 
with each other.
In the present study, we have found a higher hunger sensation 
before dinner. This effect was not observed prior to breakfast or 
lunch. In the Spanish way of life, lunch is the main meal of the 
day, so it is expected to be the moment when orlistat could have 
the greatest effect on postprandial triglycerides. Unfortunately, 
we did not clearly define the postprandial response, but there are 
many studies that showed the effect of orlistat on postprandial 
triglyceride response to a meal (11,12).
It has been previously postulated that orlistat may increase 
appetite because it accelerates gastric emptying (28,29). We 
found three randomized controlled studies comparing the use of 
orlistat to a placebo in appetite after an ingested meal. In a study 
by Ellrichman et al. (7), the administration of orlistat led to a 15% 
reduction in satiety ratings and a 24% increase in appetite, with 
a 31% of prospective food consumption. But in both Demarchi et 
al. (6) and Goedecke et al. (5) studies, orlistat was not shown to 
alter hunger, satiety, prospective consumption or fullness rates, 
while examining changes over time. 
It is the first time that it is possible to study the impact of orlistat 
on serum leptin without the confounding effect of weight loss and 
diet. The patients in our study did not lose weight because they 
did not make any qualitative or quantitative change in their diet 
and follow-up time was only two days. In our study, reductions in 
plasma triglycerides were found to be directly related to decreases 
in circulating levels of leptin. Moreover, this hunger increase is 
related to a decrease in plasma triglycerides. It is well established 
that orlistat reduces plasma triglycerides. 
We have found a link between hunger sensation and orlistat 
induced leptin and triglycerides decrease. It is difficult to explain 
why we observed increased appetite only just before dinner after 
treatment with orlistat. The reason may be that in Spain lunch is 
the main meal, where triglycerides (TGL) intake is higher than in 
breakfast. Thus, the effect of orlistat on postprandial TGL could be 
higher after lunch than after breakfast. If we assume that appetite 
sensation depends on the absorption of postprandial TGL, these 
would further decrease after lunch than after breakfast. Unfortu-
nately, we did not measure TGL after breakfast, lunch or dinner to 
determine the possible different effect of orlistat on postprandial 
TGL in the different meals.
Several other limitations exist in the present study: placebo 
controlled trial and postprandial lipemia or fecal fat excretion 
induced by orlistat were not determined. But, to our knowledge, 
there are currently no other published data on the effect of short 
term orlistat treatment on circulating leptin levels in humans with-
out weight changes. Moreover, we have observed a relationship 
between this change in plasma leptin with hunger sensation and 
variations in plasma triglycerides. Hence, our finding is of rele-
vance in day-to-day clinical practice, where restricting diet is a 
very difficult treatment method.
In conclusion, these data suggest that plasma leptin concentra-
tion is rapidly regulated by factors other than changes in fat cell 
mass. Partial fat malabsorption induced by treatment with orlistat 
quickly reduces plasma triglycerides and leptin. This plasma tri-
glycerides decrease could be an important regulation factor of 
leptin secretion. Furthermore, this decrease in plasma leptin was 
associated with increased appetite before intake following the 
main meal of the day.
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